Price
$1.73
Decreased by -7.49%
Dollar Volume (20D)
89.9 K
ADR%
6.7
Shares Float
2.17 B
Shares Outstanding
7.3 M
Shares Short
37.75 K
Market Cap.
14.23 M
Beta
0.74
Price / Earnings
N/A
20D Range
1.84 2.35
50D Range
1.8 3.25
200D Range
1.55 5.41
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 31, 23 0
Decreased by N/A%
-
Mar 2, 23 0
Decreased by N/A%
-1.8
Increased by +100%
Nov 30, 22 0
Decreased by N/A%
-
Aug 30, 22 -0.24
Decreased by -77.14%
-0.24
Jun 1, 22 0
Increased by +100%
-
Feb 28, 22 0
Increased by +100%
-
Dec 1, 21 0
Increased by +100%
-
Aug 30, 21 -0.13
Decreased by -5.7 K%
-0.17
Increased by +22.35%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 N/A
Decreased by -100%
N/A
Increased by +100%
- -
Mar 31, 23 N/A
Decreased by -100%
N/A
Increased by +100%
- -
Dec 31, 22 812.12 K
Decreased by -5.25%
-2.73 M
Decreased by -14.31%
Decreased by -336.65%
Decreased by -20.64%
Sep 30, 22 762.98 K
Decreased by -10.49%
-2.57 M
Decreased by -7.98%
Decreased by -336.65%
Decreased by -20.64%
Jun 30, 22 954.27 K
Increased by +3.62%
-2.16 M
Increased by +14.53%
Decreased by -226.58%
Increased by +17.52%
Mar 31, 22 1.03 M
Increased by +10.87%
-2.34 M
Increased by +8.55%
Decreased by -226.58%
Increased by +17.52%
Dec 31, 21 857.08 K
Increased by +18.05%
-2.39 M
Increased by +27.54%
Decreased by -279.06%
Increased by +38.62%
Sep 30, 21 852.43 K
Increased by +26.44%
-2.38 M
Increased by +22.38%
Decreased by -279.06%
Increased by +38.62%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.